Mankind Pharma Limited

Issue Size (Net)

up to Rs.4326.36 Cr

Price Band

1026 to 1080 per share

Issue Opens

25-Apr-23

Issue Closes

27-Apr-23

Company Highlights Financials Highlights Issue Details Prospectus

Company Highlights

1.Company Information

Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.

In India, the business is active in a number of acute and chronic therapeutic fields, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.

It has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among them.

Mankind Pharma has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market ("IPM"). Over 80% of doctors in India prescribed their formulations and has been ranked number 4th in terms of domestic sales during the Financial Year 2022.

The company has been awarded The Best of Bharat Awards 2022 by exchange4media in the year 2022, Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for Manufacturing, and Silver Award for Good Health Brand at IHW Awards 2021 in the year 2021, Best Condom Brand of the Year award at Sex Brand Awards Pharma OTC Company of the Year Award at Pharma Excellence Awards 2018, Award for Best Design in Healthcare at Healthcare Leadership Awards 2017, and Amity HR Excellence Award for Performance Management at the 8th Global HR Summit 2011.

2. Objective of the Issue

The Company proposes to utilize the Net Proceeds towards funding of the following objects:

All of the offer proceeds will be received by the selling shareholders in proportion to the offered shares that each selling shareholder sold as part of the offer; the company will not receive any of the offer proceeds.

Mankind Pharma IPO Registrar

KFin Technologies Limited

Phone:04067162222, 04079611000

Email: mankind.ipo@kfintech.com

Website: https://karisma.kfintech.com/

Mankind Pharma Limited Financial Information (Restated Consolidated)

Period Ended	Total Assets	Total Revenue	Profit After Tax	Net Worth
31-Mar-20	5,073.29	5,975.65	1,056.15	3,485.31
31-Mar-21	6,372.63	6,385.38	1,293.03	4,722.00
31-Mar-22	9,147.74	7,977.58	1,452.96	6,155.23
Amount in Rs. Crore

Mankind Pharma Limited IPO Details

Issue Opening Date	25 Apr-23
Issue Closing Date	27 Apr-23
Face Value	Rs.1 per share
Price	1026 to 1080 per share
Lot Size	13 Shares
Issue Size	40,058,844 shares (aggregating up to Rs.4326.36 Cr)
Offer for Sale	40,058,844 shares (aggregating up to Rs.4326.36 Cr)
Issue Type	Book Built Issue IPO
Listing At	BSE, NSE
QIB Shares Offered	50% of the Offer
NII (HNI) Shares Offered	15% of the Offer
Retail Shares Offered	35% of the Offer

Prospectus

Prospectus File

Download